Pfizer Inc. ($PFE) Stock Forecast: Up 2.5% Today

What is Pfizer Inc.?

Pfizer Inc. ($PFE) is a global pharmaceutical company known for its innovative healthcare products. Today, the stock experienced a strong bullish movement in the market.

Why is Pfizer Inc. going up?

PFE stock is up 2.5% on Jan 6, 2026 15:41

• Pfizer announced a strategic collaboration with Cartography Biosciences to discover tumor-selective antigens, possibly boosting investor confidence in the company's future growth prospects.
• The increase in stake by Torray Investment Partners LLC indicates a positive sentiment towards Pfizer's stock, contributing to the bullish movement.
• The positive results announced by Alumis for its psoriasis pill may have indirectly impacted Pfizer's stock, as it highlights advancements in the pharmaceutical industry, including potential future collaborations and developments.
• Despite Gateway Investment Advisers LLC lowering its stock position in Pfizer, the overall increase in stake by other institutional investors and the company's strong Q3 performance likely outweighed this negative news, driving the bullish movement.

PFE Price Chart

PFE Technical Analysis

PFE News

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

Cartography Biosciences announced a strategic collaboration with Pfizer to discover tumor-selective antigens using Cartography's ATLAS and SUMMIT platforms. Cartography will receive up to $65 million in upfront and near-term milestone payments, with potential total deal value exceeding $850 million including future milestones and royalties. Pfizer will lead therapeutic development, while Cartography retains full ownership of its lead program, CBI-1214.

https://www.businesswire.com/news/home/20260106591786/en/Cartography-Biosciences-and-Pfizer-to-Collaborate-on-the-Discovery-of-Tumor-Selective-Antigens

Torray Investment Partners LLC Acquires 102,107 Shares of Pfizer Inc. $PFE

Torray Investment Partners LLC increased its stake in Pfizer Inc. by 15.7% in the third quarter, acquiring 102,107 additional shares to bring its total holdings to 752,997 shares, valued at approximately $19.19 million. Pfizer, which constitutes 2.6% of Torray Investment Partners LLC's holdings, recently declared a quarterly dividend of $0.43 per share, representing a 6.8% yield. Analyst sentiment on PFE is mixed, with a consensus "Hold" rating and an average target price of $28.06, following several brokerages lowering their price targets or downgrading the stock.

https://www.marketbeat.com/instant-alerts/filing-torray-investment-partners-llc-acquires-102107-shares-of-pfizer-inc-pfe-2026-01-06/

Psoriasis pill brings completely clear skin for over 40% of patients

Alumis (ALMS) announced positive topline results for its oral TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis from Phase 3 ONWARD1 and ONWARD2 trials. The drug demonstrated superior skin clearance compared to placebo and apremilast, with 65% of patients achieving PASI 90 and over 40% achieving PASI 100 at Week 24. Alumis plans to submit a New Drug Application (NDA) in the second half of 2026.

https://www.stocktitan.net/news/ALMS/alumis-envudeucitinib-delivers-leading-skin-clearance-among-next-vrgzpuetyg28.html

Sulfasalazine Market Is Booming Worldwide 2026-2033 | Pfizer

The Sulfasalazine Market is projected to grow from USD 2.24 Bn in 2025 to USD 3.3 Bn in 2032, exhibiting a CAGR of 5.7%. This growth is driven by innovation, investment, and shifting regional dynamics, particularly impacting key players like Pfizer Inc., Teva Pharmaceuticals USA Inc., and Ipca Laboratories Ltd. The market research report provides insights into investment hotspots, segmentation by type, application, and region, and profiles of leading companies.

https://www.openpr.com/news/4337670/sulfasalazine-market-is-booming-worldwide-2026-2033-pfizer

Gateway Investment Advisers LLC Lowers Stock Position in Pfizer Inc. $PFE

Gateway Investment Advisers LLC significantly reduced its stake in Pfizer Inc. by 94.8% in Q3, selling over a million shares and retaining 58,831 shares worth approximately $1.499 million. Despite this reduction, other institutional investors have mostly increased their positions, with hedge funds and institutions collectively owning 68.36% of Pfizer's stock. Pfizer reported Q3 EPS of $0.87, beating estimates, and announced a quarterly dividend of $0.43 per share, yielding 6.8%.

https://www.marketbeat.com/instant-alerts/filing-gateway-investment-advisers-llc-lowers-stock-position-in-pfizer-inc-pfe-2026-01-06/

Trending Today

Moderna Inc. ($MRNA) Stock Forecast: Up 6.1% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Down 5.8% Today

Voya Financial Inc. ($VOYA) Stock Forecast: Down 4.9% Today

Mobileye Global ($MBLY) Stock Forecast: Down 5.1% Today

Cassava Sciences, Inc. ($SAVA) Stock Forecast: Down 5.2% Today

State Street Corporation ($STT) Stock Forecast: Down 5.1% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Down 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.0% Today

Draftkings Inc ($DKNG) Stock Forecast: Down 7.7% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 8.2% Today

Pfizer Inc. Price History

30.09.2025 - PFE Stock was up 0.5%

• Despite the bearish options activity detected by investors, Pfizer's stock saw a significant bullish movement, indicating a potential divergence between options trading sentiment and actual market performance.
• Criticism of Plug Power and positive outlook on Sempra did not directly impact Pfizer's bullish movement, suggesting that company-specific news may not have been the primary driver of today's market activity.
• The -1.09% drop in Pfizer's stock price in the latest trading session may have been overshadowed by broader market gains, leading to the overall bullish movement observed.
• With Pfizer's Q3 earnings expected to decline, the market's bullish response today could be attributed to other factors such as positive industry developments or investor sentiment shifting towards pharmaceutical stocks in general.

05.07.2025 - PFE Stock was up 5.0%

• Strong bullish movement attributed to impressive Q2 earnings, beating estimates with significant growth in earnings and revenues.
• Rising sales in oncology drugs like Vyndaqel, Comirnaty, and Paxlovid, as well as cost-cutting measures expected to save billions by 2027, fueled the positive market response.
• Optimism further boosted by the company's raised 2025 EPS guidance and expectations of continued strength in key products like Vyndaqel and Padcev.
• President Trump's ultimatum to lower drug prices may have influenced the overall positive sentiment, potentially benefiting companies like Pfizer in the long run.

30.08.2025 - PFE Stock was up 5.7%

• Pfizer's stock saw a surge following reports of an agreement with President Trump to lower drug prices voluntarily, showcasing a positive impact on the company's reputation and potential market growth.
• Despite legal challenges related to Depo-Provera brain tumor claims, the news did not notably affect the stock's performance today, with investors focusing on the favorable developments.
• The acquisition of Metsera by Pfizer for next-generation weight loss drugs is viewed as a strategic maneuver that could enhance innovation and research expenditure, bolstering the optimistic sentiment.
• Despite a recent stock price decline, today's bullish movement demonstrates resilience and investor confidence in Pfizer's future prospects, especially with the spotlight on a potential drug-pricing arrangement.

04.10.2025 - PFE Stock was up 0.2%

• Pfizer's stock showed strong bullish movement today after surpassing earnings and revenue estimates for the third quarter of 2025, displaying robust financial performance.
• The market responded positively to Pfizer increasing its profit guidance despite a slight decline in sales, reflecting investor confidence in the company's ability to overcome obstacles and sustain profitability.
• The updated proposal from Novo Nordisk to acquire Metsera might have influenced market sentiment, potentially bolstering Pfizer's position in the pharmaceutical sector as competitors seek strategic acquisitions.
• Overall, Pfizer's strong performance in core drug sales and positive profit outlook in a challenging market environment likely contributed to the bullish movement in its stock price today.

16.11.2025 - PFE Stock was down 5.1%

• The bearish movement in Pfizer's stock today could be attributed to profit-taking by investors after a recent bullish run or concerns about competition in the pharmaceutical sector.
• The call-put ratio for Cintas Corp. (CTAS) and the positive outlook on Microsoft Corporation (MSFT) and Regeneron Pharmaceuticals, Inc. (REGN) might have diverted investor attention away from Pfizer.
• Institutional accumulation in Sealed Air Corporation (SEE) and AbbVie Inc. (ABBV) could have signaled more attractive investment opportunities compared to Pfizer, leading to the bearish movement in its stock.
• Overall, Pfizer's bearish movement today may be a short-term market correction influenced by broader market trends and investor sentiment towards other pharmaceutical companies.

16.11.2025 - PFE Stock was down 4.4%

• Pfizer's bearish movement today is linked to the company's projection of lower profits in 2026 due to an expected decrease in COVID product sales and revenue loss from drugs losing exclusivity. This information likely sparked concerns among investors regarding the company's future earnings.
• Despite confirming its 2025 earnings guidance, Pfizer's updated revenue forecast slightly below Street expectations potentially let down investors, resulting in a sell-off of the stock.
• The institutional accumulation trend in other pharmaceutical companies like Regeneron Pharmaceuticals and AbbVie, accompanied by analyst upgrades and positive earnings, may have diverted investor focus from Pfizer, contributing to the downward movement in its stock price today.
• Shorepoint Capital Partners LLC's investment in Pfizer, coupled with adjustments in holdings by other institutional investors, demonstrates sustained interest in the company despite the profit projection and revenue worries, hinting at a possible stock rebound in the future.

10.10.2025 - PFE Stock was down 2.2%

• The bearish movement in Pfizer's stock could be attributed to the uncertainty surrounding the fierce bidding war with Novo Nordisk over the acquisition of Metsera, Inc., a significant deal worth $10 billion. The market might be reacting negatively to the potential financial implications and risks associated with this high-stakes competition.
• Additionally, Trump's Most Favored Nation (MFN) policy aimed at reducing U.S. drug prices could be adding pressure on Pfizer and other pharmaceutical companies, leading to concerns about future revenue streams and profitability.
• The court's decision to deny Pfizer's request for a temporary restraining order to block Novo Nordisk's bid for Metsera might have further fueled investor uncertainty and contributed to the bearish sentiment surrounding Pfizer's stock.
• Overall, the combination of the bidding war, drug pricing concerns, and legal setbacks could have collectively influenced the bearish market movement for Pfizer today. Investors are likely closely monitoring the developments in these ongoing battles and policy changes to assess the company's future performance.

01.09.2025 - PFE Stock was up 7.7%

• The stock of Pfizer witnessed a significant surge in the market today.
• An agreement on drug pricing with President Donald Trump has fueled this bullish movement, indicating promising prospects for the company's future revenue and competitive position.
• Investor confidence in Pfizer received a boost from this agreement, which also eased industry concerns regarding potential tariff impacts, resulting in a positive market trend.
• Positive remarks from Mark Cuban regarding Trump's online pharmacy initiative and its potential enhancements may have contributed to the optimistic outlook on Pfizer's stock.
• The collaboration between Pfizer and the U.S. government to lower drug prices has not only enhanced the company's stock performance but has also underscored its dedication to addressing healthcare affordability challenges.

01.09.2025 - PFE Stock was up 7.4%

• Pfizer's stock experienced a bullish movement following reports of an agreement with President Donald Trump to lower drug prices. This news likely boosted investor confidence in the company's future prospects.
• The deal with Trump and the positive response from the pharmaceutical industry regarding Pfizer's tariff situation provided a favorable outlook for the company, leading to increased buying interest in the stock.
• Mark Cuban's assessment of Trump's online drug store venture and the upcoming court hearing over Depo-Provera brain tumor claims may have added some volatility to Pfizer's stock but did not deter the overall bullish sentiment driven by the drug pricing deal announcement.
• Overall, the market movement of Pfizer today can be attributed to a combination of positive news related to drug pricing agreements and potential challenges the company may face in the legal arena.

01.09.2025 - PFE Stock was up 7.5%

• Pfizer's stock surged due to a significant agreement with the administration to reduce prescription drug prices, fostering optimism in the pharmaceutical sector.
• Granting Pfizer a three-year exemption from pharmaceutical tariffs by the administration enabled the company to provide medications at reduced prices, bolstering investor confidence.
• The agreement not only benefited Pfizer but also had broader implications for companies such as CVS Health, Eli Lilly, and UnitedHealth Group.
• Market response indicates that Pfizer's strategic decisions and alignment with government policies have positioned it favorably, leading to a bullish trend in its stock price.

25.07.2025 - PFE Stock was down 2.1%

• Pfizer's (PFE) stock price sharply declined today, despite a recent uptrend in the past month, potentially indicating profit-taking or shifting market sentiment.
• Despite reports of major investors taking bullish positions on Pfizer, the market movement appeared bearish today. It's crucial to recognize that multiple factors beyond investor sentiment can influence market dynamics.
• The bearish trend could be linked to overall market movements, industry-specific updates, or internal developments impacting Pfizer's stock negatively.
• Investors are advised to monitor forthcoming announcements or updates regarding Pfizer to gain insights into the causes behind today's market downturn.

06.00.2026 - PFE Stock was up 2.5%

• Pfizer announced a strategic collaboration with Cartography Biosciences to discover tumor-selective antigens, possibly boosting investor confidence in the company's future growth prospects.
• The increase in stake by Torray Investment Partners LLC indicates a positive sentiment towards Pfizer's stock, contributing to the bullish movement.
• The positive results announced by Alumis for its psoriasis pill may have indirectly impacted Pfizer's stock, as it highlights advancements in the pharmaceutical industry, including potential future collaborations and developments.
• Despite Gateway Investment Advisers LLC lowering its stock position in Pfizer, the overall increase in stake by other institutional investors and the company's strong Q3 performance likely outweighed this negative news, driving the bullish movement.